Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACcomplisH China
NCT05246033Phase 2Completed
- Sponsor
- VISEN Pharmaceuticals
- Start
- Jan 2022
- Primary completion
- Mar 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of navepegritide in achondroplasia (ACH), sponsored by VISEN Pharmaceuticals. Started Jan 2022; status: completed.
02
Drugs
navepegritide
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on NCT05246033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05246033.